BACKGROUND: 1,5-Anhydroglucitol (1,5-AG), fructosamine, and glycated albumin are of increasing interest as alternative measures of hyperglycemia. We characterize the associations of these nontraditional glycemic markers with hemoglobin A(1c) (Hb A(1c)) and fasting glucose and assess their ability to identify people with diabetes. METHODS: We conducted a cross-sectional comparison of 1,5-AG, fructosamine, and glycated albumin with Hb A(1c) and fasting glucose measurements in 1719 participants from the Atherosclerosis Risk in Communities Study. We evaluated nonlinear relationships using R(2) and F-statistics. Performance for identification of cases of diabetes was determined using the area under the curve (AUC). Diabetes was defined by Hb A(1c) ≥6.5%, fasting glucose ≥126 mg/dL (≥6.99 mmol/L), and/or a self-reported history of diagnosed diabetes. RESULTS: Median values of Hb A(1c) and fasting glucose were 5.8% and 109 mg/dL (6.05 mmol/L), respectively; 17.3% of the study population had diagnosed diabetes. Glycated albumin, fructosamine, and 1,5-AG were more strongly correlated with Hb A(1c) compared with fasting glucose (all P values <0.05). Nonlinear models provided the best fit for describing the relationships of the alternative markers to Hb A(1c). When diabetes was defined by an Hb A(1c) ≥6.5%, fructosamine (AUC 0.83; 95% CI, 0.79-0.87) and glycated albumin (AUC 0.87; 95% CI, 0.83-0.90) performed comparably to fasting glucose (AUC 0.83; 95% CI, 0.79-0.87), while 1,5-AG performed worse (AUC 0.74; 95% CI, 0.69-0.78) for identifying cases of undiagnosed diabetes. CONCLUSIONS: Fructosamine and glycated albumin may be useful adjuncts to Hb A(1c) and fasting glucose. Future studies should examine these markers in situations in which fasting glucose or Hb A(1c) measurements are invalid or not available.
BACKGROUND:1,5-Anhydroglucitol (1,5-AG), fructosamine, and glycated albumin are of increasing interest as alternative measures of hyperglycemia. We characterize the associations of these nontraditional glycemic markers with hemoglobin A(1c) (Hb A(1c)) and fasting glucose and assess their ability to identify people with diabetes. METHODS: We conducted a cross-sectional comparison of 1,5-AG, fructosamine, and glycated albumin with Hb A(1c) and fasting glucose measurements in 1719 participants from the Atherosclerosis Risk in Communities Study. We evaluated nonlinear relationships using R(2) and F-statistics. Performance for identification of cases of diabetes was determined using the area under the curve (AUC). Diabetes was defined by Hb A(1c) ≥6.5%, fasting glucose ≥126 mg/dL (≥6.99 mmol/L), and/or a self-reported history of diagnosed diabetes. RESULTS: Median values of Hb A(1c) and fasting glucose were 5.8% and 109 mg/dL (6.05 mmol/L), respectively; 17.3% of the study population had diagnosed diabetes. Glycated albumin, fructosamine, and 1,5-AG were more strongly correlated with Hb A(1c) compared with fasting glucose (all P values <0.05). Nonlinear models provided the best fit for describing the relationships of the alternative markers to Hb A(1c). When diabetes was defined by an Hb A(1c) ≥6.5%, fructosamine (AUC 0.83; 95% CI, 0.79-0.87) and glycated albumin (AUC 0.87; 95% CI, 0.83-0.90) performed comparably to fasting glucose (AUC 0.83; 95% CI, 0.79-0.87), while 1,5-AG performed worse (AUC 0.74; 95% CI, 0.69-0.78) for identifying cases of undiagnosed diabetes. CONCLUSIONS:Fructosamine and glycated albumin may be useful adjuncts to Hb A(1c) and fasting glucose. Future studies should examine these markers in situations in which fasting glucose or Hb A(1c) measurements are invalid or not available.
Authors: David E Goldstein; Randie R Little; Rodney A Lorenz; John I Malone; David M Nathan; Charles M Peterson Journal: Diabetes Care Date: 2003-01 Impact factor: 19.112
Authors: I R Jones; D R Owens; S Williams; R E Ryder; A J Birtwell; M K Jones; K Gicheru; T M Hayes Journal: Diabetes Care Date: 1983 Sep-Oct Impact factor: 19.112
Authors: John B Buse; Jennifer L R Freeman; Steven V Edelman; Lois Jovanovic; Janet B McGill Journal: Diabetes Technol Ther Date: 2003 Impact factor: 6.118
Authors: Elizabeth Selvin; Lesley M A Francis; Christie M Ballantyne; Ron C Hoogeveen; Josef Coresh; Frederick L Brancati; Michael W Steffes Journal: Diabetes Care Date: 2011-02-18 Impact factor: 19.112
Authors: Ananth U Nayak; Martin R Holland; David R Macdonald; Alan Nevill; Baldev M Singh Journal: Diabetes Care Date: 2011-06-29 Impact factor: 19.112
Authors: Christina M Parrinello; A Richey Sharrett; Nisa M Maruthur; Richard M Bergenstal; Morgan E Grams; Josef Coresh; Elizabeth Selvin Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Christina W Chen; Christiane Drechsler; Pirianthini Suntharalingam; S Ananth Karumanchi; Christoph Wanner; Anders H Berg Journal: Clin Chem Date: 2016-10-13 Impact factor: 8.327
Authors: Casey M Rebholz; Morgan E Grams; Yuan Chen; Alden L Gross; Yingying Sang; Josef Coresh; Elizabeth Selvin Journal: Am J Epidemiol Date: 2017-10-15 Impact factor: 4.897
Authors: Aldin Malkoc; David Probst; Chi Lin; Mukund Khanwalker; Connor Beck; Curtiss B Cook; Jeffrey T La Belle Journal: J Diabetes Sci Technol Date: 2017-03-16
Authors: Elizabeth Selvin; Andreea M Rawlings; Pamela L Lutsey; Nisa Maruthur; James S Pankow; Michael Steffes; Josef Coresh Journal: Circulation Date: 2015-05-28 Impact factor: 29.690